BR112021021306A2 - Ecas9 modificada com ampliação da faixa de alvo de dna - Google Patents

Ecas9 modificada com ampliação da faixa de alvo de dna

Info

Publication number
BR112021021306A2
BR112021021306A2 BR112021021306A BR112021021306A BR112021021306A2 BR 112021021306 A2 BR112021021306 A2 BR 112021021306A2 BR 112021021306 A BR112021021306 A BR 112021021306A BR 112021021306 A BR112021021306 A BR 112021021306A BR 112021021306 A2 BR112021021306 A2 BR 112021021306A2
Authority
BR
Brazil
Prior art keywords
ecas9
modified
target range
dna target
range amplification
Prior art date
Application number
BR112021021306A
Other languages
English (en)
Portuguese (pt)
Inventor
Le Cong
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of BR112021021306A2 publication Critical patent/BR112021021306A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112021021306A 2019-04-25 2020-04-24 Ecas9 modificada com ampliação da faixa de alvo de dna BR112021021306A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962838498P 2019-04-25 2019-04-25
PCT/US2020/029855 WO2020219908A1 (en) 2019-04-25 2020-04-24 Engineered cas9 with broadened dna targeting range

Publications (1)

Publication Number Publication Date
BR112021021306A2 true BR112021021306A2 (pt) 2022-02-01

Family

ID=72941444

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021306A BR112021021306A2 (pt) 2019-04-25 2020-04-24 Ecas9 modificada com ampliação da faixa de alvo de dna

Country Status (12)

Country Link
US (1) US20220204954A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958914A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022530055A (cg-RX-API-DMAC7.html)
KR (1) KR20220025708A (cg-RX-API-DMAC7.html)
CN (1) CN114206394A (cg-RX-API-DMAC7.html)
AU (1) AU2020261071A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021021306A2 (cg-RX-API-DMAC7.html)
CA (1) CA3137903A1 (cg-RX-API-DMAC7.html)
IL (1) IL287541A (cg-RX-API-DMAC7.html)
MX (1) MX2021012966A (cg-RX-API-DMAC7.html)
SG (1) SG11202111814XA (cg-RX-API-DMAC7.html)
WO (1) WO2020219908A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
US20230295611A1 (en) * 2022-03-01 2023-09-21 Versitech Limited Cas9 protein for genome editing
CN115083532B (zh) * 2022-06-21 2024-08-27 中国科学技术大学 基于分子动力学模拟获取rsv f突变体的方法
CN115927439B (zh) * 2022-08-29 2026-04-21 中国农业科学院作物科学研究所 CRISPR/SaCas9系统在大豆基因编辑中的应用
AU2024309386A1 (en) 2023-06-30 2025-12-18 Christiana Care Gene Editing Institute, Inc. Nras gene knockout for treatment of cancer
CN117866926B (zh) * 2024-03-07 2024-08-16 珠海舒桐医疗科技有限公司 一种CRISPR-FrCas9蛋白突变体及应用
WO2025213016A2 (en) 2024-04-04 2025-10-09 Christiana Care Gene Editing Institute, Inc. Crispr/cas gene editing of neh4 and/or neh5 domains in nrf2
WO2025226816A1 (en) 2024-04-23 2025-10-30 Christiana Care Gene Editing Institute, Inc. Methods of identifying and correlating crispr-induced exon skipping to phenotypic outcomes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016226077B2 (en) * 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
WO2016205759A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
US9512446B1 (en) * 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2018027078A1 (en) * 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
KR102569848B1 (ko) * 2016-12-23 2023-08-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Pcsk9의 유전자 편집
JP6628387B2 (ja) * 2017-09-05 2020-01-08 国立大学法人 東京大学 改変されたCas9タンパク質及びその用途

Also Published As

Publication number Publication date
MX2021012966A (es) 2022-04-06
CN114206394A (zh) 2022-03-18
AU2020261071A1 (en) 2021-11-25
US20220204954A1 (en) 2022-06-30
EP3958914A4 (en) 2023-07-19
CA3137903A1 (en) 2020-10-29
WO2020219908A1 (en) 2020-10-29
KR20220025708A (ko) 2022-03-03
SG11202111814XA (en) 2021-11-29
EP3958914A1 (en) 2022-03-02
IL287541A (en) 2021-12-01
JP2022530055A (ja) 2022-06-27

Similar Documents

Publication Publication Date Title
MX2021012966A (es) Cas9 diseñado con intervalo de dirección de adn ampliado.
BR112022003970A2 (pt) Métodos e composições para integração genômica
WO2020030984A3 (en) Compositions and methods for genome engineering with cas12a proteins
WO2019009682A3 (ko) 표적 특이적 crispr 변이체
MX2023001538A (es) Composiciones y metodos para inhibir la expresion de lpa.
EP4253551A3 (en) Novel crispr dna and rna targeting enzymes and systems
MX2024010722A (es) Objetivos geneticos para el direccionamiento de fijacion de nitrogeno para mejorar los rasgos de las plantas.
MX2023009345A (es) Compuestos, composiciones y metodos de uso de estos.
ZA202202628B (en) Novel crispr dna targeting enzymes and systems
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
MX2025009289A (es) Inserciones de adn no virales orientadas
MX2020006072A (es) Métodos y composiciones relacionados con cpf1 para la edición genica.
MX2019009361A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
WO2020086144A3 (en) APPLICATIONS OF CRISPRi IN HIGH THROUGHPUT METABOLIC ENGINEERING
WO2019209885A3 (en) Enzyme engineering to alter the functional repertoire of cannabinoid synthases
EP4328303A3 (en) Novel use
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
WO2017053431A3 (en) Allele selective gene editing and uses thereof
BR112016028255A2 (pt) agentes imunorreguladores
BR112017024534A2 (pt) sistemas de rna-guia/endonuclease cas9 inovadores
WO2015112896A3 (en) Methods and compositions for sequences guiding cas9 targeting
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
MX2018001617A (es) Composiciones de crispr-cas9 diseñados y metodos de uso.
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
WO2018094356A3 (en) Compositions and methods for target nucleic acid modification

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2824 DE 18/02/2025.